<code id='08C558019A'></code><style id='08C558019A'></style>

<acronym id='08C558019A'></acronym>

<center id='08C558019A'><center id='08C558019A'><tfoot id='08C558019A'></tfoot></center><abbr id='08C558019A'><dir id='08C558019A'><tfoot id='08C558019A'></tfoot><noframes id='08C558019A'>

<optgroup id='08C558019A'><strike id='08C558019A'><sup id='08C558019A'></sup></strike><code id='08C558019A'></code></optgroup>

<b id='08C558019A'><label id='08C558019A'><select id='08C558019A'><dt id='08C558019A'><span id='08C558019A'></span></dt></select></label></b><u id='08C558019A'></u>

~~<i id='08C558019A'><strike id='08C558019A'><tt id='08C558019A'><pre id='08C558019A'></pre></tt></strike></i>~~

Home» Wikipedia» focus

focus

focus

author：Wikipedia 2025-10-01 15:32:55 Page View：63

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

advertisement

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： General Catalyst, Summa Health deal will turn on physician buy
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

comprehensive

Hollywood unions extend contract negotiations for actors

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

Novo: Oral version of Ozempic leads to 15% weight loss

Novo: Oral version of Ozempic leads to 15% weight loss

LISELOTTESABROE/AFP/GettyImagesAnoralversionofsemaglutide,thedrugmarketedasOzempicandWegovy,ledtodra

Bright Health sells Medicare Advantage business to Molina

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

ARCH Venture Partners is raising $3 billion for a life sciences fund

AdobeARCHVenturePartners,oneofthetopinvestorsinthebiotechecosystem,israising$3billionforanewfund.The

read more